Board of Directors

Ms. Carmichael has over 30 years of diverse executive management and board of director experience spanning from start-up and growth companies to multinationals.

Dianne was Chairman & CEO of a publicly traded investment firm before shifting to healthcare to make a difference in the lives of those touched by profound illness. As President of Best Doctors Inc., she helped create a remote second opinion platform that connected patients with the top 2% of medical experts worldwide and which today, covers over 40 million international patients. Most recently she was President Payer Markets and Head of Corporate Strategy and M&A at McKesson, a Fortune 500 healthcare company. Prior to that, Dianne was President, UHN Solutions at UHN, Canada’s leading group of research hospitals, and Managing Director, MaRS Health Ventures and Innovation. Today, Ms. Carmichael continues to make a difference for patients by helping health-tech companies bring high impact innovations to scale globally through her company, Carmichael Worldwide Inc. Dianne formerly served as the Chief Advisor for the HealthTech division of the Council of Canadian Innovators, founded by Jim Balsillie, where they bring the voice of Canadian tech CEOs to government and policy makers.

Dianne has served on numerous healthcare boards, including Holland Bloorview Kids Rehab Hospital, PatientsCanada, CAPCH, Centre for Regenerative Medicine, Mt. Sinai’s Personalized Medicine Institute & W.I.N.

She was awarded Canada’s Most Powerful Women by WXN, Canadian Women Transforming Health Care and University of Waterloo Alumni of the Year. She holds a B.A. from the University of Waterloo.

Mr. Burton is a co-founder of Bloom Burton & Co. and serves as the firm’s President and Head of Investment Banking. As trusted advisors to boards of directors, management teams, and professional and strategic investors, Jolyon and his team help structure and execute financial and capital markets strategies, mergers and acquisitions or other partnering transactions. The team has been directly involved in financings of over $1 billion as well as mergers and acquisitions transactions valued at more than $2 billion. In the role immediately preceding the co-founding of Bloom Burton, Jolyon served as the Head of Healthcare & Biotechnology Investment Banking at an independent investment dealer. Jolyon started his career in roles that helped internationally focused growth companies, both at Export Development Canada and Global Affairs Canada.

Mr. Burton serves as a Director of Grey Wolf Animal Health. He is a graduate of the University of Waterloo with an Honours Bachelor of Arts in Applied Studies, with a Major in Economics and Specializations in Finance and International Trade and received the Department of Economics award for academic achievement among his graduating class.

Mr. Chicoine is currently the Executive Chairman of Crescita Therapeutics Inc. (TSX:CTX ), where he oversees the investor relations function, and advises management on certain strategic business development projects from time to time. From March 1, 2016 until April 2, 2018, Mr. Chicoine served as Crescita’s Chairman and Interim Chief Executive Officer, at which time he was succeeded by Mr. Verreault. Mr. Chicoine served as Nuvo Research’s Chairman and Co-CEO and was actively involved in its day-to-day operations from 2004 to 2016 when Crescita became a reporting issuer following the reorganization of Nuvo Research into two separate publicly traded entities, Crescita and Nuvo Pharmaceuticals Inc. Prior to 2004, Mr. Chicoine held various senior executive positions at the Magna International group of companies, including President and Chief Executive Officer and Chief Financial Officer, and was the President of PowerCart Systems Inc., a Markham-based private company that designs and manufactures battery-equipped workstations that power devices with wireless communication capability. Mr. Chicoine is a graduate of the University of Toronto in commerce and is a Chartered Professional Accountant.

Mr. Cucuz is the Chief Executive Officer of Greybrook Securities, Inc. since 2005, where he directs Greybrook’s capital markets activities across the firm’s focus areas in real estate and healthcare. Operationally, Mr. Cucuz co-manages Greybrook Realty Partners’ business across both its Asset Management and Capital Markets verticals. Mr. Cucuz also serves as the Co-chair of Greybrook’s Advisory Committee for all active limited partnerships which include more than 50 real estate developments with an estimated completion value of approximately $14 billion, and the Co-chair of Greybrook’s investment committee. As the former CEO of Greybrook Health, Mr. Cucuz played a critical role in the launch of Greenbrook TMS and Greybrook’s prior portfolio acquisitions of MacuHealth and Bruder Health Care. He currently serves on the board of Greenbrook TMS, as well as on the boards of a number of Greybrook affiliated companies and the Blu Genes Foundation. After receiving a Bachelor of Arts in Economics from York University in 2000, Sasha went on to play professional hockey for three seasons. Mr. Cucuz began his career at TD Securities and CIBC before founding Greybrook Capital with his partners.

Mr. Legault is the CEO of Antibe Therapeutics (TSXV:ATE) since 2009. Trained as a corporate lawyer and as an air force rescue pilot, Mr. Legault’s career has evolved to focus on high-growth, mostly technology-based companies. His CEO-level experience includes organizations specializing in data analytics, IT and consumer marketing. Mr. Legault has served on the boards of directors of International Save the Children and of Green Shield Canada, a leading health benefits administrator. Mr. Legault continues to serve as a board member and advisor to several companies and not-for-profit organizations. Mr. Legault is a member of the Law Society of Upper Canada and the New York State Bar.

Mr. Ram is a finance executive with over 10 years of experience working in the healthcare industry. Between 2018 and 2019, Mr. Ram served as Chief Executive Officer and Executive Director of NeuPath, and has served on the board of directors of NeuPath since February 2018. Mr. Ram acted as the COO of InMedic Creative Medicine from 2011 to December 2019, prior to and following its acquisition by NeuPath in 2018. Mr. Ram holds a Bachelor of Science, Finance from DePaul University.

Mr. Joseph Walewicz was Executive Vice President, Business and Corporate Development of Clementia Pharmaceuticals, a NASDAQ-listed company, from 2017 to 2019 prior to Clementia’s acquisition by Ipsen Pharmaceuticals for US$1 billion in April of 2019. Mr. Walewicz has spent 25 years in biopharma, serving on the board and at the executive level of multiple publicly traded biopharma companies including Clementia Pharmaceuticals, MethylGene (now Mirati Therapeutics Inc.), Warnex Inc. and Paladin Labs, and as a top ranked equities analyst for major banks including CIBC, BMO, Lehman Brothers where he covered publicly traded North American biotechnology, pharmaceuticals, medtech and healthcare services companies. Mr. Walewicz holds a Master of Business Administration, Finance (McGill), as well as a Bachelor of Science, Biochemistry, and a Bachelor of Arts, Economics from Queen’s University. Mr. Walewicz is also a CFA (Chartered Financial Analyst) charterholder and a member of the Licensing Executives Society (LES).